Home > Haematology > ASH 2019 > Plenary Scientific Session > Mosunetuzumab: complete remissions in non-Hodgkin lymphoma

Mosunetuzumab: complete remissions in non-Hodgkin lymphoma

Presented By
Prof. Stephen Schuster, University of Pennsylvania, USA
ASH 2019
The bispecific anti-CD3 and anti-CD20 monoclonal antibody mosunetuzumab provided durable responses in patients with B-cell non-Hodgkin lymphoma, even in relapsed patients or patients whose disease was refractory to chimaeric antigen receptor (CAR) T-cell therapy. The dose-escalation trial, presented by Prof. Stephen J. Schuster (University of Pennsylvania, USA), enrolled patients with B-cell non-Hodgkin lymphoma who had received at least 1 prior therapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and for whom there was “no available therapy that would be expected to improve survival” [1]. A total of 270 patients (median age 62 years) were enrolled; 164 of those (61.2%) had an ECOG performance status of 1, and 180 (66.7%) were categorised as having aggressive non-Hodgkin lymphoma. The most common diagnosis was diffuse large B-cell lymphoma (DLBCL; n=117, 43.3%), followed by transformed follicular lymphoma (FL; n=32...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on